How GLP-1 Drugs Affect the Body's Ability to Recover from Low Blood Sugar | Research

The takeaway

A review examines how incretin-based therapies and elevated GLP-1 may impair counterregulatory responses to hypoglycemia in diabetes patients.

Potential counterregulatory impairment
GLP-1 and incretin drugs may affect the body's protective response to low blood sugar

What the researchers found

Evidence suggests elevated GLP-1 and incretin-based therapies may impair counterregulatory responses to hypoglycemia, particularly in patients with pre-existing hypoglycemia unawareness.

Why it matters

Hypoglycemia unawareness is dangerous and can cause seizures, coma, or death. Understanding whether GLP-1 drugs affect counterregulation is a critical safety question.

How the study worked

Narrative review synthesizing preclinical and clinical evidence on GLP-1/incretin effects on hypoglycemia counterregulation.

What this study cannot tell us

Much evidence from animal models; clinical data in humans is limited; mechanisms may differ between type 1 and type 2 diabetes.

How to read the evidence

Narrative review — raises an important safety hypothesis based on mixed preclinical and limited clinical evidence.

When this study was published

Published 2026 in Diabetes Research and Clinical Practice.

The bigger picture

As GLP-1 RAs are increasingly used alongside insulin (in both T1D and T2D), understanding their impact on hypoglycemia defense mechanisms is essential for safety.

Questions still open

Should GLP-1 RA users with hypoglycemia unawareness have modified treatment protocols?
Do different GLP-1 RAs vary in their effects on counterregulation?

Common questions

Can GLP-1 drugs cause low blood sugar?

GLP-1 drugs rarely cause hypoglycemia on their own, but this review raises concerns that they may impair the body's ability to recover when blood sugar does drop too low, especially in patients taking insulin.

What is hypoglycemia unawareness?

It's a dangerous condition where people with diabetes can't feel the warning signs of low blood sugar (shaking, sweating, confusion), putting them at risk of severe episodes.

Read the original research

The impact of GLP-1 and incretin-based therapies on counterregulatory responses to hypoglycemia in diabetes mellitus: mechanisms and clinical implications.

Diabetes research and clinical practice, 233, 113155

View on PubMed ↗Publisher’s paper ↗

Citation

Balakumar, Pitchai; Khan, Noohu Abdulla; Easwaran, Vigneshwaran; Orayj, Khalid M. (2026). The impact of GLP-1 and incretin-based therapies on counterregulatory responses to hypoglycemia in diabetes mellitus: mechanisms and clinical implications.. Diabetes research and clinical practice, 233, 113155. https://doi.org/10.1016/j.diabres.2026.113155